ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07729046 (Neu Direction), which is not on this map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07729046 phase2not yet recruitingnot on this mapstarted 2027, after this paper: background citation
Neu Direction: A Single Center Phase II Randomized Clinical Trial to Assess the Efficacy of Adding HER Inhibition to Standard of Care in Patients With Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
Who cites it
55 citing papers in PubMed, 85 citations in OpenAlex.
- ATR inhibition potentiates the antitumor efficacy of HER3-DXd in HER3-positive/HR-positive breast cancer by increasing DNA damage.British journal of cancer · 2026Article
- Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence.Nature communications · 2025Article
- CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?International journal of molecular sciences · 2025Review
- Advances in diagnostic and therapeutic applications of mismatch repair loss in cancer.DNA repair · 2025Review
- Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours.Communications biology · 2025Article
- CD4Science advances · 2025Article
- Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology.Trends in cancer · 2025Review
- Research progress on the role of the NEIL family in cancer.Frontiers in cell and developmental biology · 2025Review
- Article
- CRISPR/Cas9-mediated silencing of CD44: unveiling the role of hyaluronic acid-mediated interactions in cancer drug resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Irreversible inhibition of estrogen receptor α signaling and the emergence of hormonal resistance in MCF7 breast cancer cells induced by DNA damage agents.Biomedical reports · 2024Article
- DNA damage targeted therapy for advanced breast cancer.Exploration of targeted anti-tumor therapy · 2024Review
- ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.NPJ breast cancer · 2023Article
- Article
- Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.Science advances · 2023Article
- Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations.Discover oncology · 2023Review
- Positive p53 Expression Is Associated with Primary Endocrine Therapy Resistance in Locally Advanced Stage Luminal B HER2-Negative Breast Cancer Patients: A Cross-Sectional Study in Indonesia.Diagnostics (Basel, Switzerland) · 2023Article
- High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism.Frontiers in endocrinology · 2023Review
- RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Meenakshi AnuragDepartment of Medicine, Baylor College of Medicine, Houston, Texas.
Nindo PunturiDepartment of Medicine, Baylor College of Medicine, Houston, Texas.
Jeremy HoogSiteman Cancer Center Breast Cancer Program, Washington University School of Medicine, St. Louis, Missouri.
Matthew N BainbridgeDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
Matthew J EllisDepartment of Medicine, Baylor College of Medicine, Houston, Texas. Svasti.Haricharan@bcm.edu Matthew.Ellis@bcm.edu.ORCID 0000-0002-8467-8534
Svasti HaricharanDepartment of Medicine, Baylor College of Medicine, Houston, Texas. Svasti.Haricharan@bcm.edu Matthew.Ellis@bcm.edu.
Baylor College of Medicine · USBreast Cancer Research Foundation · USChildren’s Institute · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MStatistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0MWashington University/ Siteman Cancer Center Lead Academic SiteU10CA180833 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L, KOZOWER, BENJAMIN D · 2014 to 2018
$7.6MUT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)U10CA180858 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUNT, KELLY K, PINNIX, CHELSEA CAMILLE · 2014 to 2018
$5.6MWUSM CANCER AND LEUKEMIA GROUP BU10CA077440 · NCI · WASHINGTON UNIVERSITY · PI BARTLETT, NANCY L · 1998 to 2013
$4.4MA pan-cancer role for MutL loss in inducing treatment resistanceK22CA229613 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HARICHARAN, SVASTI · 2018 to 2020
$442kNCI NIH HHS K22 CA229613NCI NIH HHS U10 CA077440NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180833NCI NIH HHS U10 CA180858NCI NIH HHS U10 CA180882
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic Agents, HormonalAromatase InhibitorsBreast NeoplasmsCalcium-Binding ProteinsCell Cycle ProteinsDNA-(Apurinic or Apyrimidinic Site) LyaseDNA-Binding ProteinsDNA GlycosylasesDNA RepairDrug Resistance, NeoplasmEndonucleasesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHeterograftsAntineoplastic Agents, HormonalAromatase InhibitorsCalcium-Binding ProteinsCell Cycle ProteinsCETN2 protein, humanDNA-(Apurinic or Apyrimidinic Site) LyaseDNA-Binding ProteinsDNA GlycosylasesEndonucleasesERCC1 protein, humanNEIL2 protein, humanReceptors, EstrogenTamoxifen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07729046ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.